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Summary
Background.  —  Infarct  size  (IS)  is  a  major  determinant  of  patient  outcome  after  acute  ST-
segment  elevation  myocardial  infarction  (STEMI).  Interventions  aimed  at  reducing  reperfusion
injury, such  as  cardiac  ischaemic  postconditioning  (IPost),  may  reduce  IS  and  improve  clini-
cal outcomes.  IPost  has  been  shown  to  be  feasible  in  patients  with  STEMI  treated  by  primary
percutaneous  coronary  intervention  (PPCI).
Aims.  —  To  provide  an  updated  summary  of  the  efﬁcacy  of  IPost,  assessed  by  analysing  accurate
surrogate  markers  of  IS.
Methods.  —  We  performed  a  meta-analysis  of  randomized  controlled  trials  that  evaluated  the
efﬁcacy of  IPost  in  STEMI  patients  undergoing  PPCI.  The  main  outcome  was  area  under  the
curve of  serum  creatine  kinase  release  (CK-AUC).  Secondary  outcomes  were  other  surrogate
biomarkers  of  IS,  complete  ST-segment  resolution,  direct  measurement  of  IS  by  single-photon
emission computed  tomography  and  estimation  of  IS  by  cardiac  magnetic  resonance  (CMR-IS).
Results. —  Eleven  studies  were  retrieved,  including  1313  STEMI  patients  undergoing  PPCI  with  or
without IPost.  Compared  with  controls,  we  observed  a  signiﬁcant  reduction  in  CK-AUC  (standard
mean difference  [SMD]  —2.84  IU/L,  95%  CI  —5.43  to  —0.25  IU/L;  P  =  0.03).  Other  surrogate  mark-
ers, such  as  CMR-IS  (SMD  —0.36,  95%  CI  —0.88  to  0.15;  P  =  0.16),  showed  a  non-signiﬁcant  IS
reduction in  the  IPost  group.
Conclusions.  —  This  meta-analysis,  dealing  with  accurate  surrogate  markers  of  IS,  suggests  that
IPost reduces  IS.  However,  results  should  be  interpreted  cautiously  because  of  limited  sam-
ple sizes  and  signiﬁcant  heterogeneity.  Whether  this  translates  into  improvements  in  cardiac
function and  patient  prognosis  still  needs  to  be  demonstrated  in  larger  prospective  randomized
controlled  studies  that  are  powered  sufﬁciently.
© 2014  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Objectifs.  —  Synthétiser  les  données  actuelles  de  la  science  concernant  l’efﬁcacité  du  postcon-
ditionnement  ischémique  sur  la  réduction  de  taille  d’infarctus  du  myocarde  (IDM).
Pré-requis.  —  La  taille  d’IDM  est  un  déterminant  majeur  du  pronostic  des  patients  au  décours
d’un STEMI.  Les  interventions  visant  à  protéger  des  lésions  de  reperfusion  comme  le  postcondi-
tionnement  ischémique  pourraient  réduire  la  taille  d’IDM  et  améliorer  le  pronostic.  Des  essais
cliniques  ont  montré  que  le  postconditionnement  ischémique  était  réalisable  chez  les  patients
revascularisés  par  angioplastie  primaire  à  la  phase  aiguë  d’un  STEMI.
Méthodes.  —  Nous  avons  réalisé  une  méta-analyse  des  essais  thérapeutiques  randomisés  et  con-
trôlés évaluant  l’efﬁcacité  du  postconditionnement  ischémique  à  la  phase  aiguë  d’un  STEMI
revascularisé  par  angioplastie  primaire.  Le  critère  majeur  était  l’aire  sous  la  courbe  (AUC)  des
CPK. Les  critères  secondaires  étaient  d’autres  biomarqueurs  de  taille  d’IDM,  la  résolution  du
segment ST,  et  la  taille  d’IDM  estimée  par  scintigraphie  ou  IRM  myocardique.
Résultats.  —  Onze  études  incluant  1313  patients  ont  été  retenues.  Notre  analyse  objective  une
réduction  signiﬁcative  de  l’AUC  des  CPK  (SMD  −2,84,  95  %  CI  −5,43,  −0,25  IU/L,  p  =  0,03)  dans
le groupe  actif.  Elle  montre  une  tendance  non  signiﬁcative  en  faveur  de  cette  même  réduction
dans le  groupe  actif  sur  les  autres  marqueurs  de  substitution  comme  l’IRM  (SMD  −0,36,  95  %  CI
−0,88, 0,15,  p  =  0,16).
Conclusions.  —  Nos  résultats  suggèrent  que  le  postconditionnement  ischémique  réalisé  lors  de  la
revascularisation  d’un  STEMI  par  angioplastie  primaire  permet  d’obtenir  une  réduction  de  taille
d’IDM. Ces  résultats  sont  à  interpréter  avec  prudence  en  raison  de  la  petite  taille  des  effectifs
et d’une  hétérogénéité  signiﬁcative.  Des  essais  thérapeutiques  contrôlés  sur  de  larges  effectifs
sont nécessaires  pour  démontrer  l’efﬁcacité  de  cette  réduction  sur  des  critères  cliniques  et  sur
le pronostic  des  patients.
© 2014  Elsevier  Masson  SAS.  Tous  droits  réservés.
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tackgroundespite  current  optimal  treatment,  coronary  heart  disease
orbidity  and  mortality  remain  signiﬁcant,  paving  the  way
or  the  development  of  new  cardioprotective  therapies  [1].
H
l
bimely  reperfusion  is  the  most  effective  treatment  to  reduce
he  size  of  an  infarct  resulting  from  myocardial  ischaemia.
owever,  reperfusion  has  the  potential  to  induce  additional
ethal  injury,  identiﬁed  as  reperfusion  injury,  which  can
e  responsible  for  up  to  40%  of  the  ﬁnal  infarct  size  (IS).
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Because  IS  is  known  to  be  a  major  determinant  of  patient
prognosis,  any  intervention  that  reduces  its  extent  may
result  in  a  clinical  beneﬁt  [2].
Ischaemic  preconditioning  and  postconditioning  are
interventions  with  multiple  and  interacting  components
marshalled  against  myocardial  reperfusion  injury  by  endoge-
nous  cardioprotective  mechanisms  [3].  Cardiac  ischaemic
postconditioning  (IPost)  is  deﬁned  as  rapid  intermittent
interruptions  of  blood  ﬂow  in  the  early  phase  of  myocardial
reperfusion,  feasible  in  patients  with  ST-segment  elevation
myocardial  infarction  (STEMI)  revascularized  by  primary  per-
cutaneous  coronary  intervention  (PPCI)  [3].
Most  clinical  trials  evaluating  the  beneﬁt  of  IPost  were
small  single-centre  studies  that  reported  conﬂicting  results
regarding  IS  reduction  [4,5].  Three  meta-analyses  inves-
tigating  the  effect  of  IPost  have  already  been  published
[6—8].  These  meta-analyses  either  used  suboptimal  surro-
gate  markers  of  myocardial  IS,  such  as  peak  necrosis  marker
levels,  or  combined  different  markers  in  the  same  analy-
sis.  More  evidence  is  needed  before  recommending  IPost  in
routine  clinical  practice.
The  aim  of  this  systematic  review  and  meta-analysis  was
to  provide  an  updated  summary  of  published  randomized  tri-
als  investigating  the  efﬁcacy  of  IPost  using  reliable  surrogate
markers  of  IS  reduction.
Methods
This  review  was  conducted  and  reported  according  to  the
Preferred  Reporting  Items  for  Systematic  reviews  and  Meta-
Analyses  (PRISMA)  criteria  [9].
Information sources and search strategy
We  searched  electronic  databases  (PubMed,  Cochrane)  for
studies  published  before  December  2013.  In  order  to  have
comparable  information  from  eligible  studies,  we  collected
additional  data  by  communicating  directly  with  the  authors.
The  following  keywords  were  used:  ‘‘ischaemic  postcon-
ditioning’’;  ‘‘myocardial  infarction’’;  and  ‘‘acute  coronary
syndrome’’.  Our  search  was  restricted  to  human  and
randomized  controlled  studies,  without  any  language
restriction.  We  also  reviewed  the  reference  lists  of  published
meta-analyses  and  selected  studies.
Eligibility criteria and study selection
The  selection  of  eligible  studies  was  done  by  two  authors
(C.T.,  D.A.),  with  disagreements  resolved  by  consensus
between  these  two  authors.
Inclusion  criteria  were  randomized  controlled  trials
enrolling  STEMI  patients  admitted  during  the  acute  phase  for
PPCI,  comparing  IPost  (active  group)  with  a  routine  interven-
tion  (control  group),  and  evaluating  one  or  more  surrogate
markers  of  IS.  We  decided  a  priori  to  exclude  studies  that
systematically  used  intracoronary  adenosine  injection  at  the
time  of  reperfusion,  because  adenosine  is  a  known  activator
of  cardioprotective  signalling  pathways,  inducing  potential
pharmacological  conditioning,  which  may  dilute  the  effect
of  IPost  on  IS  reduction  [3].
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The  following  surrogate  markers  of  IS  were  consid-
red:  area  under  the  curve  (AUC)  of  serum  creatine
inase  (CK)  release  (CK-AUC);  AUC  of  CK  myocardial
and  release  (CKMB-AUC);  AUC  of  troponin  (T  or  I
soforms)  release  (Tropo-AUC);  complete  ST-segment  reso-
ution  (cSTR),  deﬁned  as  STR  >  70%  after  reperfusion;  direct
easurement  of  IS  by  single-photon  emission  computed
omography  (SPECT);  or  estimation  of  IS  as  a  percentage  of
he  area  at  risk  by  cardiac  magnetic  resonance  (CMR).
isk of bias in individual studies
ne  author  (C.T.)  assessed  the  methodological  quality  of  the
elected  trials  according  to  the  Cochrane  risk  of  bias  crite-
ia.  We  considered  the  following  domains:  random  sequence
eneration  and  allocation  concealment  (selection  bias);
linding  of  participants  and  personnel  (performance  bias);
linding  of  outcome  assessment  (detection  bias);  and  com-
leteness  of  the  follow-up,  intention-to-treat  (ITT)  analysis
nd  dropouts  (attrition  bias).
Based  on  the  above  criteria,  studies  were  divided  into
hree  categories:  low  (all  criteria  were  at  low  risk  of  bias);
igh  (at  least  one  criterion  was  at  high  risk  of  bias);  or
nclear  if  otherwise.
utcomes and comparisons
ur  main  outcome  was  the  effect  of  IPost  on  CK-AUC.  Sec-
ndary  outcomes  were:  other  biological  surrogate  markers
CKMB-AUC,  Tropo-AUC);  cSTR  as  a  clinical  surrogate  marker
f  ischaemia  resolution;  and  imaging  surrogate  markers  of
S,  measured  by  SPECT  (SPECT-IS)  or  estimated  by  CMR  (CMR-
S).
ata extraction process
ata  from  eligible  trials  were  extracted  by  one  author  (C.T.).
e  contacted  authors  by  e-mail  whenever  additional  data
ere  needed.
tatistical analysis
e  extracted  aggregate  data  from  published  reports.  Sum-
ary  measures  are  reported  as  standard  mean  difference
SMD)  ±  standard  deviation  for  continuous  variables  (CK-
UC,  CKMB-AUC,  Tropo-AUC,  SPECT-IS  and  CMR-IS)  as  studies
ssessed  the  same  outcome  but  measured  it  in  a  variety
f  ways.  Summary  risk  ratios  (RRs)  are  reported  for  binary
ariables  (cSTR)  with  95%  conﬁdence  intervals  (CIs).  We  used
 ﬁxed-effects  model,  and  if  signiﬁcant  heterogeneity  was
bserved,  a  random-effects  model  was  performed.  If  het-
rogeneity  persisted  after  using  a  random-effects  model,
e  then  performed  a  sensitivity  analysis,  by  excluding  one
rial  at  a  time.  We  tried  to  explore  heterogeneity  further  by
onsidering  characteristics  at  both  trial  and  patient  levels.
n  inverse-variance  model  was  used  to  pool  the  data.  Sta-
istical  heterogeneity  across  trials  was  assessed  with  Chi2,  I2nd  Tau2 statistics.  Heterogeneity  was  considered  signiﬁcant
f  the  P  value  was  <  0.1  and  heterogeneity  was  considered
igh  if  I2 was  >  50%.  Risk  of  bias  assessment  by  visual  inspec-
ion  of  funnel  plot  was  not  relevant  due  to  the  small  number
42  C.  Touboul  et  al.
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iigure 1. Flow diagram of study selection.
f  included  studies.  Statistical  analyses  were  performed
sing  RevMan  software  (version  5.1).
esults
ncluded studies
he  numbers  of  studies  identiﬁed  at  each  stage  of  the  sys-
emic  review  are  shown  in  Fig.  1.  After  removing  duplicate
eferences,  the  searches  identiﬁed  595  records.  Based  on
itle  and/or  abstract,  37  relevant  articles  were  retrieved
or  full-text  reading.  We  excluded  22  articles  for  the  fol-
owing  reasons:  16  were  not  randomized  controlled  trials;
hree  were  meta-analyses;  one  did  not  report  any  surro-
ate  marker  of  IS;  and  two  dealt  with  the  same  database  as
ligible  studies.  We  excluded  a  further  two  trials  that  sys-
ematically  used  intracoronary  adenosine  injection  at  the
ime  of  reperfusion  and  two  trials  published  in  Chinese
10,11],  as  we  did  not  succeed  in  obtaining  data  from  the
uthors.  Eleven  studies  [4,5,12—22]  were  ﬁnally  included  in
his  review,  corresponding  to  1313  patients  (646  randomized
o  the  IPost  group  and  667  to  the  control  group)  (Table  1).
dditional  data  were  obtained  by  contacting  the  authors  of
hree  studies  [4,17,18].  The  studies  by  Lonborg  et  al.  [14,15]
nd  Thuny  et  al./Mewton  et  al.  [17,20]  were  reported  in  two
w
a
o
3ublications  each,  so  we  included  the  data  as  one  study  only
or  each  group.
Patients  had  a  mean  age  of  60.4  years  and  were  pre-
ominantly  men  (Table  1).  Patient  exclusion  criteria  in  the
ncluded  studies  were  homogenous:  cardiac  arrest;  cardio-
enic  shock;  left  main  coronary  artery  occlusion  or  severe
tenosis;  blood  ﬂow  in  the  infarct-related  artery  >  throm-
olysis  in  myocardial  infarction  (TIMI)  grade  1  at  the  time  of
he  diagnosis  coronary  angiography;  obvious  coronary  col-
aterals  to  the  risk  region;  previous  myocardial  infarction  or
reinfarction  angina  within  48  hours;  prior  coronary  bypass
urgery  or  PCI;  and  left  bundle  branch  block.  IPost  pro-
ocols  were  different  in  the  various  studies  but  were  all
erformed  within  1  minute  of  reﬂow  with  balloon  reinﬂa-
ion  at  4  to  6  atm  (Fig.  2).  Three  studies  [5,17,19,20]  came
rom  the  same  research  group  and  used  the  same  IPost  pro-
ocol,  with  four  cycles  of  1  minute  of  balloon  reinﬂation
bove  the  index  lesion  followed  by  1  minute  of  reperfusion
mmediately  after  direct  stenting.  IPost  protocols  were  sim-
lar  in  three  other  studies  [4,13,18], but  balloon  reinﬂation
as  performed  at  the  same  location  as  the  PPCI  inside  the
mplanted  stent.  In  the  ﬁve  other  studies,  the  IPost  protocol
as  performed  before  stent  implantation,  just  after  balloon
ngioplasty:  four  cycles  of  1  minute  of  inﬂation  and  1  minute
f  deﬂation  [21]  or  four  cycles  of  30  seconds  of  inﬂation  and
0  seconds  of  deﬂation  [14,15]  with  stent  implantation  left
M
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Table  1 Main  study  characteristics.
Studies  Number  of  patients Mean  age
(years)
Men/women
(n/n)
Ischaemia
duration  (hours)
IPost
protocol
Culprit  arterya Summary
risk  of  bias
Outcomes
reported
IPost Control  IPost Control
Yang  et  al.,  2007  [22] 23  18  61  31/10 5.2  4.4  30  s ×  3 LAD  >  RCA  >  LCX U  CK-AUC;  cSTR;
SPECT-IS
Ma  et  al.,  2006  [16] 47  47  64  64/30 6.6  7.1  30  s ×  3 LAD  >  RCA  >  LCX H
Staat  et  al.,  2005  [5] 16  14  57  25/5 5.3  5.5  60  s ×  4 RCA  >  LAD U  CK-AUC
Thibault  et  al.,  2008  [19] 17  21  56  25/13 4.7  4.9  60  s ×  4 LAD  >  RAD L  CK-AUC;
Tropo-AUC;
SPECT-IS
Lonborg  et  al.,  2010  [14,15] 59b 59b 62  92/26 4.0  4.3  30  s ×  4 RCA  >  LAD  >  LCX U  cSTR;  CMR-IS
Sorensson  et  al.,  2010  [18]  45b 45b 63  65/25  2.8  3.1  60  s  ×  4  RCA  >  LAD  >  LCX  U  CKMB-AUC;
Tropo-AUC;
CMR-IS
Freixa  et  al.,  2012  [4]  39b 40b 60  62/17  5.4  5.0  60  s ×  4  LAD  >  RCA  L  cSTRc;  CMR-IS
Fan  et  al.,  2011  [12] 22  28  66  31/19  MD  MD  30  s ×  3  MD  U
Thuny  et  al.,  2012  [17,20] 25  25  57  37/13 4.8  3.6  60  s ×  4  LAD  >  RCA  >  LCX  U  CMR-IS
Xue  et  al.,  2010  [21] 23  20  58  41/2  4.1  5.4  60  s ×  4  LAD  >  RCA  U  CKMB-AUC;
cSTR;
SPECT-ISd
Hahn  et  al.,  2013  [13] 350  350  60  537/163 3.3  3.2  60  s ×  4  LAD  >  RCA  >  LCX  L  cSTR
Total 646  667  60.4
AUC: area under the curve; CK: creatine kinase; CKMB: creatine kinase myocardial band; CMR: cardiac magnetic resonance; cSTR: complete ST-segment resolution; H: high risk of bias;
IPost: ischaemic postconditioning; IS: infarct size; L: low risk of bias; LAD: left anterior descending artery; LCX: left circumﬂex artery; MD: missing data; RCA: right coronary artery;
SPECT: single-photon emission computed tomography; U: unclear risk of bias.
a Culprit artery: refers to the most frequent location (in percentages) of the artery responsible for ST-segment elevation myocardial infarction in each article.
b Not intention-to-treat.
c Results were reported as average STR in each group (instead of cSTR deﬁned by STR > 70%) and hence could not be used for the quantitative meta-analysis.
d Results were reported in the form of a score (semi-quantitative method) and hence could not be used for the quantitative meta-analysis.
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Figure 2. Different ischaemic postconditioning (IPost) protocols
performed in studies included in the qualitative analysis. Stent
implantation was performed using direct stenting or after ﬁrst bal-
loon inﬂation or after IPost sequences. Brackets indicate that stent
implantation was not part of the protocol and was therefore left
to the operator’s preference. Black squares represent intracoro-
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iary balloon reinﬂation (at 4 to 6 atm) after revascularization and
ocalization inside the infarct-related artery.
o  the  discretion  of  the  operator;  three  cycles  of  30  seconds
f  inﬂation  and  30  seconds  of  deﬂation  followed  by  stenting
12,22]  or  without  stenting  [16].
Only  three  studies  [4,13,19]  were  at  low  risk  of  bias  for
ll  considered  criteria,  and  one  [16]  was  considered  at  high
isk  of  bias  because  of  a  randomization  method  based  on  the
ate  of  admission.  The  other  seven  studies  were  considered
s  having  an  unclear  risk  of  bias  (Table  1).
Eight  studies  provided  at  least  partial  data  on  IS  surro-
ates  (Table  1)  and  could  be  included  in  the  quantitative
nalysis.  Three  studies  provided  data  on  CK-AUC,  two  on
KMB-AUC,  two  on  Tropo-AUC,  four  on  cSTR,  three  on
PECT-IS  (although  one  [21]  presented  results  in  a  way  that
revented  comparison  with  the  results  from  the  two  other
tudies)  and  four  on  CMR-IS.
urrogates biomarkers of infarct size: CK-AUC,
KMB-AUC and Tropo-AUC
Post  was  associated  with  a  signiﬁcant  reduction  in  CK-AUC
SMD  —2.84  IU/L,  95%  CI  —5.43  to  —0.25  IU/L;  P  =  0.03)  in
hree  studies  [5,19,22]  (Fig.  3),  but  with  signiﬁcant  het-
rogeneity  (Chi2 =  47.1,  P  <  0.001;  I2 =  96%;  Tau2 =  4.88).  In
he  sensitivity  analysis,  heterogeneity  disappeared  with  the
xclusion  of  the  study  by  Yang  et  al.  [22];  this  study  was  dif-
erent  from  the  two  other  studies  [5,19]  regarding  patient
roﬁles  (more  hypertension  and  diabetes)  and  patient  selec-
ion  (no  age  limitation,  no  speciﬁcation  for  the  time  from
hest  pain  onset  to  PPCI).  Of  note,  the  two  other  studies
T
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ere  performed  by  the  same  research  group.  CK  dosage
ethods  were  different  in  the  study  by  Yang  et  al.  (auto-
ated  analyser  Synchron  LX20;  Beckman  Coulter,  Brea,  CA,
SA)  compared  with  the  other  two  studies  (CK  Kit;  Beckman
oulter).  In  addition,  the  IPost  protocol  was  different  in  the
tudy  by  Yang  et  al.  compared  with  the  other  two  studies
Fig.  2).
IPost  was  not  associated  with  a signiﬁcant  reduction  in
KMB-AUC  (SMD  —0.35  IU/L,  95%  CI  —0.96  to  0.26  IU/L;
 =  0.27)  in  two  studies  [18,21]  (Fig.  3),  with  moderate
eterogeneity  (Chi2 =  2.58;  P  =  0.11;  I2 =  61%;  Tau2 =  0.12).
eterogeneity  between  the  two  studies  could  be  explained
y  the  use  of  different  dosage  methods  for  blood  analysis  and
y  fewer  blood  samplings  in  the  study  by  Xue  et  al.  [21].
IPost  was  not  associated  with  a signiﬁcant  reduction  in
ropo-AUC  (SMD  —0.28  IU/L,  95%  CI  —1.04  to  0.48  IU/L;
 =  0.48)  in  two  studies  [18,19]  (Fig.  3),  with  signiﬁcant  het-
rogeneity  between  studies  (Chi2 =  3.67;  P  =  0.06;  I2 =  73%;
au2 =  0.22).  Heterogeneity  between  the  two  studies  could
e  explained  by  the  use  of  different  troponin  isoforms  (iso-
orm  I  in  the  study  by  Thibault  et  al.  [19]  versus  isoform  T
n  the  study  by  Sorensson  et  al.  [18])  and  different  dosage
ethods.
linical surrogate of ischaemia resolution:
STR
Post  was  not  associated  with  a  signiﬁcantly  improved  cSTR,
ith  only  10%  patients  experiencing  STR  >  70%  after  IPost  in
our  studies  [13—15,21,22]  (RR  1.10,  95%  CI  0.95  to  1.27;
 =  0.20),  with  signiﬁcant  heterogeneity  between  studies
Chi2 =  6.56;  P  =  0.09;  I2 =  54%)  (Fig.  4).
In  addition  to  the  different  IPost  protocols  across  studies
Table  1  and  Fig.  2),  heterogeneity  may  also  be  explained  by
he  different  timings  for  ST-segment  resolution  evaluation:
20  minutes  for  Xue  et  al.  and  Yang  et  al.  [21,22], 90  minutes
or  Lonborg  et  al.  [14,15]  and  30  minutes  for  Hahn  et  al.  [13].
f  note,  different  methods  were  used  for  electrocardiogram
nalysis:  a  trained  technician  for  Xue  et  al.  [21], dedicated
oftware  (LIFENET)  for  Lonborg  et  al.  [14,15],  a  cardiologist
or  Yang  et  al.  [22]  and  an  independent  laboratory  for  Hahn
t  al.  [13].
maging surrogates of infarct size: SPECT-IS (%
f the LV) and CMR-IS (% of the LV)
Post  was  not  associated  with  a  signiﬁcant  reduction  in
PECT-IS  (SMD  —0.42,  95%  CI  —0.88  to  0.03;  P  =  0.06)  in  two
tudies  [19,22]  (Fig.  5),  without  signiﬁcant  heterogeneity
etween  studies  (Chi2 =  0.68;  P  =  0.41;  I2 =  0%).
IPost  was  not  associated  with  signiﬁcant  reduction  in
MR-IS  (SMD  —0.36,  95%  CI  —0.88  to  0.15;  P  =  0.16)  in  four
tudies  [4,14,15,17,18,20]  (Fig.  5),  with  signiﬁcant  het-
rogeneity  between  studies  (Chi2 =  13.6;  P  =  0.004;  I2 =  78%;
au2 =  0.21).  Sensitivity  analyses  did  not  identify  one  spe-
iﬁc  study  responsible  for  heterogeneity.  Forest  plot  visual
nspection  indicates  that  two  studies  (Lonborg  et  al.  and
huny  et  al./Mewton  et  al.  [14,15,17,20]) showed  signiﬁcant
eductions  in  CMR-IS,  while  the  two  others  (Freixa  et  al.  and
orensson  et  al.  [4,18])  showed  no  reduction.  This  ﬁnding
ould  be  partially  explained  by  differences  in  timing  of  CMR
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Figure 3. Forest plots of biological surrogate markers of infarct size. Results are presented as the standard (Std.) mean difference. A
random-effects model was performed. AUC: area under the curve; CI: conﬁdence interval; CK: creatine kinase; CKMB: creatine kinase
myocardial band; IPost: ischaemic postconditioning; IV: inverse-variance; SD: standard deviation; Tropo: troponin T or I.
Figure 4. Forest plot of complete ST-segment resolution (cSTR). cSTR was deﬁned as the difference in ST-segment elevation between
the baseline electrocardiogram (ECG) and the ECG recorded after reperfusion, divided by the ST-segment elevation in baseline ECG > 70%.
Results are presented as the risk ratio. A ﬁxed-effects model was performed. CI: conﬁdence interval; IPost: ischaemic postconditioning; IV:
inverse-variance.
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Figure 5. Forest plots of imaging surrogate markers of infarct size (IS). Results are presented as the standard (Std.) mean difference.
A ﬁxed-effects model was performed for SPECT-IS and a random-effects model was performed for CMR-IS. CI: conﬁdence interval; CMR:
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iardiac magnetic resonance; IPost: ischaemic postconditioning; IV: 
omputed tomography.
nalysis.  CMR  was  performed  2  days  after  admission  in  the
tudy  by  Thuny  et  al./Mewton  et  al.  [17,20],  7  days  after
dmission  in  the  studies  by  Sorensson  et  al.  and  Freixa  et  al.
4,18]  and  3  months  after  admission  in  the  study  by  Lonborg
t  al.  [14,15].
Left  ventricular  ejection  fraction  (LVEF),  measured  by
ither  transthoracic  echocardiography  or  CMR,  showed  no
igniﬁcant  differences  between  groups  at  short  (7-day)  and
ong  (6-month)  follow-up  (data  not  shown).
iscussion
ur  study  is  the  ﬁrst  meta-analysis  analysing  the  effects  of
Post  on  the  following  surrogates  of  IS:  CK-AUC,  CKMB-AUC
nd  Tropo-AUC.  Our  results  suggest  that  IPost  signiﬁcantly
ecreases  CK-AUC.  Although  not  statistically  signiﬁcant,
esults  for  CKMB-AUC,  Tropo-AUC,  cSTR,  SPECT-IS  and  CMR-
S  showed  a  trend  towards  a  beneﬁcial  effect  of  IPost.
egarding  CMR  analysis,  this  may  be  related  to  signiﬁcant
iscrepancy  between  studies  regarding  CMR  timing  after
yocardial  infarction.  In  addition,  CMR  determination  of  the
rea  at  risk  has  recently  been  the  subject  of  controversy
ecause  of  other  potential  causes  of  myocardial  oedema
23].Reducing  IS  through  the  prevention  of  reperfusion  injuries
s  a  new  frontier  in  myocardial  infarction  therapy.  Apart  from
Post,  other  procedures  have  produced  encouraging  results:
njection  of  cardioprotective  agents,  such  as  cyclosporine
s
e
I
bse-variance; SD: standard deviation; SPECT: single-photon emission
r  metoprolol  [24,25]; and  remote  ischaemic  conditioning
26,27].  So  far,  no  large  prospective  randomized  clinical  tri-
ls  with  hard  clinical  endpoints  evaluating  these  procedures
ave  been  published;  they  are  therefore  still  in  transition
rom  bench  to  bedside.  Performing  meta-analyses  combin-
ng  data  from  small  clinical  trials  may  provide  interesting
nsights  for  both  researchers  and  clinicians  regarding  the
eneﬁt  of  these  procedures.
We  can  summarize  the  results  of  the  three  meta-analyses
lready  published  [6—8]  as  follows.  The  meta-analysis  by
ansen  et  al.  [6]  published  in  2010  included  six  studies
244  patients)  and  showed  a  signiﬁcant  decrease  in  peak
K  and  an  increase  in  LVEF  in  IPost  patients  compared
ith  usual  care.  Two  recent  meta-analyses  [7,8]  published
n  2012  had  different  inclusion/exclusion  criteria,  leading
o  differences  in  included  studies  and  reported  outcomes.
he  meta-analysis  by  Wei  et  al.  [7]  included  13  studies
673  patients)  and  showed:  a  signiﬁcant  decrease  in  peak  CK;
 signiﬁcant  decrease  in  peak  CKMB;  a  signiﬁcant  reduction
n  SPECT-IS;  no  signiﬁcant  improvement  in  cSTR;  and  signif-
cant  improvement  in  long-term  LVEF.  The  meta-analysis  by
hou  et  al.  [8]  included  10  studies  (560  patients)  and  showed
 signiﬁcant  reduction  in  necrosis  biomarkers  and  signiﬁcant
mprovement  in  LVEF.
The  novelty  of  our  meta-analysis  comes  from  the  inclu-
ion  of  the  latest  and  largest  published  clinical  trial  by  Hahn
t  al.  [13],  the  analysis  of  different  surrogate  markers  of
S  and  the  methodology.  Compared  with  the  meta-analyses
y  Hansen  et  al.  and  Wei  et  al.  [6,7], we  used  AUC  and  not
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peak  of  biomarkers  as  a  surrogate  marker  for  IS.  According
to  Gibbons  et  al.  [28],  peak  CKMB  can  be  used  as  a  substitute
for  AUC  if  a  sufﬁcient  number  of  samples  are  measured  to
detect  true  peak  values.  Turer  et  al.  [29]  showed  that  peak
CK,  peak  CKMB  and  AUC  calculations  had  signiﬁcant  cor-
relation  with  functional  outcomes  (LVEF  and  SPECT-IS)  and
death  in  the  setting  of  STEMI.  Lopes  et  al.  [30]  showed  that
the  observed  CKMB  measures  (AUC  and  peak)  and  measures
obtained  from  sophisticated  curve  ﬁtting  also  had  signiﬁcant
correlations  with  clinical  endpoints,  such  as  90-day  death
and  heart  failure.  However,  this  may  not  be  true  in  studies
in  which  CKMB  values  are  measured  less  frequently.  At  least,
ﬁve  CKMB  measurements  are  necessary  to  ﬁt  a  log-normal
model  to  the  CKMB  curve.  It  is  still  possible  to  calculate
observed  CKMB-AUC  using  fewer  than  ﬁve  measurements,
but  the  validity  is  questionable  [30].  In  line  with  the  article
by  Gibbons  et  al.  [28],  we  favoured  AUC  rather  than  peak
values.  Besides,  we  analysed  IS  as  a  percentage  of  the  area
at  risk,  estimated  by  CMR  (CMR-IS)  in  four  studies,  whereas
Hansen  et  al.  [6]  did  not  consider  CMR-IS  and  Wei  et  al.  [7]
only  analysed  CMR-IS  for  two  studies.
Compared  with  the  meta-analysis  by  Zhou  et  al.  [8], we
followed  a  different  methodology:  each  myocardial  necro-
sis  biomarker  was  analysed  separately,  while  Zhou  et  al.
aggregated  all  biomarkers  (i.e.  the  more  relevant  available
marker  was  chosen  for  each  study,  resulting  in  a  non-
homogeneous  comparisons  of  IS  surrogates).
Preclinical  studies  have  suggested  that  only  the  ﬁrst
few  minutes  of  myocardial  reperfusion  following  the  index
ischaemic  period  offer  a  window  for  IPost  protection  against
ischaemia  reperfusion  injuries.  Emerging  evidence  suggests
that  several  signalling  pathways  are  recruited  at  the  time
of  myocardial  reperfusion,  including  cell-surface  receptors,
a  diverse  array  of  protein  kinase  cascades,  including  the
reperfusion  injury  salvage  kinase  (RISK)  pathway  and  the
survivor  activating  factor  enhancement  (SAFE)  pathway,
redox  signalling  and  the  mitochondrial  permeability  transi-
tion  pore  (mPTP)  [3,31].  In  addition,  signiﬁcant  myocardial
ischaemic  injury  is  needed  to  gain  any  signiﬁcant  IS  reduc-
tion  from  procedures  preventing  reperfusion  injuries.  Miura
et  al.  [32]  suggested  that  the  intervention  would  need  to  be
potent  enough  to  limit  the  fraction  of  the  risk  zone  infarcting
from  75%  in  the  untreated  patient  to  ≤  40%  in  patients  with
an  area  at  risk  that  is  >  20%  of  the  left  ventricle.  Of  note,
most  of  the  clinical  trials  included  in  our  meta-analysis  did
not  give  any  details  regarding  the  area  at  risk.
As  depicted  in  our  work,  the  IPost  protocols  dif-
fered  between  studies.  This  may  have  induced  variability
regarding  the  efﬁcacy  of  IS  reduction.  Four  studies  used
direct  stenting,  four  others  implanted  the  stent  after  the
IPost  protocol  and  four  studies  only  allowed  the  use  of
thrombus  aspiration  before  stenting  [4,13—15,17,20].  This
is  important,  because  thrombus  aspiration  may  reduce  post
PCI  distal  embolization  that  may  play  an  important  role
in  the  ‘‘no-reﬂow’’  phenomenon.  A  recent  clinical  trial
showed  no  clinical  beneﬁt  of  systematic  thrombus  aspiration
in  STEMI  patients  [33].  Some  studies  did  not  speciﬁcally  men-
tion  in  their  protocol  that  balloon  reinﬂation  was  performed
after  retraction  above  the  implanted  stent.  Balloon  reinﬂa-
tion  inside  the  implanted  stent  may  have  triggered  thrombus
fragmentation  and  distal  embolization,  leading  to  microvas-
cular  occlusion,  jeopardizing  myocardial  revascularization
r
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nd  potential  IPost  efﬁcacy  [4].  Our  data  do  not  allow  us
o  draw  any  conclusion  regarding  the  best  IPost  protocol  to
rotect  the  myocardium  against  reperfusion  injuries  at  the
ime  of  PPCI.  Of  note,  animal  models  used  to  establish  IPost
fﬁcacy  and  mechanisms  could  not  address  this  concern
ither.  In  animal  models,  myocardial  ischaemia  is  provoked
y  experimental  non-atherothrombotic  coronary  occlusion
ubsequently  revascularized  without  coronary  stenting.
As  mentioned  above,  our  meta-analysis  included  the
ecent  publication  by  Hahn  et  al.  [13]  reporting  the  largest
linical  trial  comparing  IPost  with  control  in  700  patients
ndergoing  PPCI  for  STEMI.  In  this  study,  the  primary  end-
oint  (percentage  of  ST-segment  resolution  >  70%  measured
0  minutes  after  PPCI)  was  not  different  between  treated
nd  control  groups.  The  weight  of  this  study  was  impor-
ant;  its  integration  in  our  analysis  turned  the  effect  of
Post  on  cSTR  reduction  to  statistically  non-signiﬁcant.
owever,  some  limitations  of  this  study  that  may  have
eopardized  the  potential  beneﬁcial  effect  of  IPost  need
o  be  acknowledged:  balloon  reinﬂation  within  the  stent
t  the  location  of  the  culprit  lesion;  and  a  large  num-
er  of  infarct-related  artery  predilatations  and  thrombus
spirations  before  stenting,  which  may  have  delayed  the
ubsequent  IPost  procedure.  These  limitations  have  been
iscussed  extensively  in  a  report  by  Ovize  et  al.  [34].
Although  our  meta-analysis  produced  encouraging  results
egarding  IS  reduction,  we  must  acknowledge  that  IPost  may
ot  be  easy  to  translate  into  clinical  practice  because  of
he  burden  of  immediate  balloon  reinﬂation  after  coronary
evascularization  during  PPCI.  Of  note,  preclinical  studies
ave  suggested  that  IPost  may  not  be  efﬁcient  in  patients
ith  metabolic  disorders  such  as  hyperlipidaemia  and  dia-
etes  [35].  Other  strategies,  such  as  remote  conditioning
27]  and/or  pharmacological  conditioning  [25],  may  be  eas-
er  to  translate  into  clinical  practice.
tudy limitations
ur  meta-analysis  has  several  limitations,  mainly  due  to  the
haracteristics  of  the  studies.  Included  studies  had  small
umbers  of  patients  and  poorly  reported  methodological
spects,  such  as  random  sequence  generation,  allocation
oncealment  and  performance  bias.  Of  note,  three  of  the
ncluded  studies  did  not  have  an  intention-to-treat  analy-
is  [4,14,15,18]. Several  outcomes  (CK-AUC,  Tropo-AUC  and
MR-IS)  were  heterogeneously  reported.  Methods  used  to
easure  CK-AUC  or  cSTR  were  also  heterogeneous.  This  led
s  to  present  several  Forest  plots  with  a  small  number  of
tudies  for  each  endpoint.  In  addition,  high  heterogeneity
I2 >  50%)  was  observed  for  almost  all  analysed  outcomes.
e  discussed  several  possible  causes  of  heterogeneity,  but
ould  not  identify  a  major  cause.  The  relevance  of  perform-
ng  a  meta-analysis  may  be  questionable  in  case  of  persisting
eterogeneity,  despite  the  use  of  a  random-effects  model
r  subgroup  analysis.  On  the  other  hand,  performing  a
eta-analysis  allowed  us  to  provide  graphical  representa-
ion  of  the  summary  of  evidence  regarding  IPost-related  IS
eduction;  it  also  provided  quantitative  estimates  of  such  a
eduction  on  various  outcomes,  which  could  be  taken  into
ccount  when  designing  future  clinical  trials.  Our  results
uggest  a  small  beneﬁt  of  IPost  on  surrogate  markers  of  IS,
ith  no  data  regarding  clinical  outcomes.  Both  IS  reduction
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nd  clinical  outcomes  remain  to  be  investigated  in  large
linical  trials.
onclusions
sing  CK-AUC  as  a  surrogate  marker,  our  results  suggest  a
mall  beneﬁt  of  IPost  on  IS,  which  is  a  major  determinant  of
 patient’s  clinical  outcome  after  acute  myocardial  infarc-
ion;  hence,  this  reduction  could  signiﬁcantly  improve  post
yocardial  infarction  cardiac  function  and  patient  progno-
is.  Published  clinical  trials  evaluating  IPost  were  neither
ailored  nor  conceived  to  detect  clinical  beneﬁts  on  major
dverse  cardiac  events,  such  as  heart  failure  or  mortality.
here  is  a  need  for  large  prospective  randomized  controlled
tudies  with  intention-to-treat  analysis,  using  hard  clinical
ndpoints.
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